Finch and Takeda Expand Their Collaboration to Target Crohn’s Treatment Development

Finch and Takeda Expand Their Collaboration to Target Crohn’s Treatment Development
Finch Therapeutics and Takeda Pharmaceutical are joining forces to develop a treatment for Crohn’s disease — expanding their partnership in their development program for inflammatory bowel disease (IBD), which includes an ulcerative colitis treatment candidate. The expanded agreement calls for microbiome-based treatment development using Finch’s Human-First Discovery platform, and for Takeda to get exclusive worldwide rights to commercialize a Rationally Selected Microbiota (RSM) product developed for Crohn’s. Financial terms were not disclosed. In collaboration with Takeda, Finch’s first RSM product — FIN-524 — is in preclinical development for ulcerative colitis (UC). The RSM platform uses machine-learning algorithms to mine Finch’s unique clinical datasets to identify the key microbes driving patient outcomes. “We are pleased to expand our collaboration with Takeda,” Mark Smith, PhD, Finch CEO, said in a press release. “We’ve had a very fruitful collaboration wit
Subscribe or to access all post and page content.